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704Successful Prevention of Acute Graft-versus-Host
Disease Using Low-Dose Antithymocyte Globulin after
Mismatched, Unrelated, Hematopoietic Stem Cell
Transplantation for Acute Myelogenous Leukemia
Hee-Je Kim, Woo-Sung Min, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min,
Seok Lee, Seok-Goo Cho, Jong-Youl Jin, Jong-Wook Lee, Chun-Choo KimIn this study, we investigated the effects of low-dose antithymocyte globulin (ATG, thymoglobulin) in the pre-
vention of acute graft-versus-host disease (aGVHD) in mismatched, unrelated hematopoietic stem cell trans-
plantations (uHSCTs) in patients with the single disease entity of acute myelogenous leukemia (AML).
Patients (n 5 103) with a variable risk for AML who received uHSCTs from available Asian and Caucasian
donors were enrolled. First, we compared HLA-matched (group 1, n 5 54) and HLA-mismatched (group
2, n 5 49) transplantation patients. Then, we divided the patients in group 2, who had received transplants
from allele(s)/antigen-mismatched donors, into 2 subgroups: patients who used ATG (group 3, n 5 24) and
those who did not (group 4, n5 25). To prevent the development of aGVHD, the patients in group 3 received
ATG at a dose of 1.25 mg/kg body weight per day for 2 consecutive days, together with our standard regimen
of methotrexate (MTX) and tacrolimus. The median CD341 cell infusion was 4.2 106/kg (range: 1.2-34.4).
The median patient age was 41 years (range: 16-57), and the median follow-up duration of patients who were
event-free survivors was 23 months (range: 2-72). The overall incidences of aGVHD and chronic GVHD
(cGVHD)were 38% and 56%, respectively. Of 48 evaluable patients in group 2, 10 (21%) developedmoderate
to severe aGVHD (grades II-IV). In contrast, 2 (8%) of the 24 patients in group 3 and 7 (29%) of the 24 eval-
uated patients in group 4 required therapy for aGVHD (grades II-IV; P5.038). The incidence of cGVHDwas
not different between groups 3 and 4. The estimated probabilities of overall survival (OS) and event-free sur-
vival (EFS) at 2 years for group 2 were 55% and 44%, respectively. In comparison, the estimated probabilities
of OS and EFS at 2 years for groups 3 and 4 were 68% versus 38% (P5 .043) and 58% versus 38% (P5 .103),
respectively. The overall cumulative incidence of nonrelapse mortality (NRM) was 29% in group 2. The cu-
mulative incidence of NRM differed markedly between group 3 (16%; 95% confidence interval [CI], 4%–28%)
and group 4 (44%, 95% CI, 34%–54%) (P 5 .013). We found no difference in cytomegalovirus (CMV) reac-
tivation between groups 3 and 4. These results suggest that in mismatched uHSCT, a low dose of ATG (total
2.5 mg/kg) may prevent moderate to severe aGVHD, with comparable rates of relapse and CMV reactivation
and a greatly decreased rate of NRM.
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According to reports to date, patients with acute
myelogenous leukemia (AML) can experience long-
term, disease-free survival (DSF) after unrelated
hematopoietic stem cell transplantation (uHSCT)
[1,2]. In general, perfect donor-recipient HLA match-
ing is important for optimal results in uHSCTs, and
donor-recipient mismatches are associated with in-
creased risk for various posttransplant complications
such as acute and chronic graft-versus-host disease
(aGVHD, cGVHD), graft rejection, fatal infections,
and other causes of treatment-related mortality
(TRM) [3,4]. However, to increase the available
Biol Blood Marrow Transplant 15:704-717, 2009 705Prevention of aGVHD Using Low-Dose ATGunrelated donor pool for the majority of patients who
lack HLA-matched unrelated donors, recent studies
have focused on the identification of permissible mis-
matches [5-9].
Meanwhile, the use of antithymocyte globulin
(ATG) has been introduced in several studies to pre-
vent aGVHD after HSCT from HLA-matched or
-mismatched related/unrelated donors [5,9,10-12].
Most of these studies suggest that ATG (thymoglobu-
lin; Genzyme, Cambridge, MA), at a total dose of 4.5-
15 mg/kg, reduces the risk of severe (grades III2IV)
aGVHD, but increases the risk for infection. Despite
the greatly improved clinical outcome after uHSCT,
obstacles remain, including long donor search times
and high TRM [13,14].
Our current strategy of using ATG for GVHD
prophylaxis in adult patients with AML who received
uHSCT was derived from our sad experience before
2005, as described later. Eighteen patients who re-
ceived unrelated peripheral blood stem cells
(uPBSCTs) from either HLA-matched or -mis-
matched donors did not receive ATG for GVHD pro-
phylaxis. Among 8 cases of severe aGVHD, 6 patients
who received uPBSCTs from HLA-matched donors
did not receive ATG for GVHD prophylaxis. Unfor-
tunately, 4 of them exhibited uncontrollable, severe
aGVHD, and 3 of these had extensive-type progressive
cGVHD, specifically involving the lungs, with typical
findings of bronchiolitis obliterans, combined with
other manifestations. The other 4 cases involved se-
vere gut GVHD, combined with skin aGVHD.
Thus, since 2005, we have studied the addition of
ATG, at a dose of 1.25 mg/kg body weight per day
on days23 and22 (total, 2.5 mg/kg), not only in those
receiving uHSCTs from allele(s)/antigen-mismatched
donors, but also in cases using uPBSCs as a stem cell
source. This low dose of ATG has previously been
used clinically [15].
Based on a comparison study between subgroups
of uHSCT patients among intermediate- to high-risk
patients with AML, we demonstrated that the addition
of a relatively low dose of ATG in patients who re-
ceived either uPBSCs or bone marrow (BM) from
HLA-mismatched unrelated donors was helpful in
overcoming the expected poor outcome. Furthermore,
we noted apparently paradoxic improvements in event-
free survival (EFS) and overall survival (OS) in patients
who developed mild to moderate aGVHD after receiv-
ing ATG for GVHD prophylaxis, compared with
high-risk patients with AML who did not receive
ATG [15].
In this prospective study, we investigated the ef-
fects of low-dose ATG in uHSCTs in patients with
a single disease entity, AML. To reduce nonrelapse
mortality (NRM), particularly in the HLA-mis-
matched setting, ATG may play an important role inimmunosuppression, thereby providing survival bene-
fits and reducing detrimental aGVHD.MATERIALS AND METHODS
Patient Characteristics
We present the results of uHSCTs from available
Asian and Caucasian donors. Korean patients with
intermediate- and high-risk AML who did not have
suitable HLA-matched related donors were enrolled.
Consecutive adult patients who had AML (n 5 103)
and a variety of baseline clinical findings underwent
transplantation at the Catholic Hemopoietic Stem
Cell Transplantation Center, The Catholic University
of Korea, Seoul, Korea, starting in December 2001,
with follow-up through the end of December 2007
(Table 1). Among this population, we focused on pa-
tients who received transplants from allele(s)/antigen-
mismatched unrelated donors (n 5 49). The median
patient age was 41 years (range: 16257 years), and
the median follow-up duration of patients who were
event-free survivors was 23 months (range: 2272
months). We divided these patients into 2 groups, ac-
cording to the use of ATG (group 3, n5 24) or nonuse
of ATG (group 4, n 5 25) (Table 2). Group 4, the
historic control population, received uHSCT between
2001 and 2005, and group 3 received uHSCT and
ATG between 2005 and 2007. All patients and donors
provided written informed consent. The treatment
protocol was approved by the institutional review
board of The Catholic University of Korea.
We screened all patients and donors for HLA-A,
-B, -Cw, and -DRB1 alleles, using a high-resolution
(DNA sequencing) molecular typing method. Accord-
ing to our policy for locating unrelated donors, we be-
gan with a search of domestic donor registries; if no
match was found, we then searched the Asian donor
registries ( Japan and Taiwan); and if we still found no
match, we searched the American (National Marrow
Donor Program, NMDP) and European (Zentrales
Knochenmarkspender-Register Deutschland, ZKRD)
donor registries. The median time to transplantation
from complete remission (CR) was 6 months (range:
2210). All patients undergoing posttransplant fol-
low-up were included in the long-term follow-up
analysis (Table 1).
Cytogenetic risk groups were classified using the
guidelines from the Southwest Oncology Group
(SWOG) trial [16]. Briefly, patients with normal karyo-
types in addition to18,2Y,16, and del(12p), identified
at presentation, were considered to be at intermediate
risk (n 5 63). Except for the presence of t(15;17) or
inv(16)/t(16;16)/del(16q) with any other abnormality,
and t(8;21) without del(9q), all other specific cytoge-
netic abnormalities were deemed unfavorable (n5 40).
Table 2. Comparison of Transplant Characteristics between
Groups 3 and 4.
Group 3 Group 4
Year 2005-2007 Year 2001-2005
Variables (n 5 24) (n 5 25) P
Donor age,
median years (range)
30 (2343) 28 (2053) NS
Donor sex,
male : female
18:6 17:8 NS
Patient age,
median years (range)
45 (1657) 40 (1851) NS
Patient sex,
male : female
19:5 18:7 NS
Cytogenetic abnormalities NS
Intermediate risk 14 16
High risk 10 9
HLA mismatches NS
1 allele 13 12
2 alleles 1 3
1 antigen 6 8
1 allele+1 antigen 4 2
Source of stem cells .03
Bone marrow 9 24
Peripheral blood 15 1
Donor registries NS
Korean 17 15
Taiwanese 2 7
Japanese 1 3
Caucasian 4 0
CMV serology, donor/recipient NS
+/+ 18 17
+/2 3 8
2/+ 3 2
2/2 0 0
Pretransplant status NS
1st complete remission 17 17
2nd complete remission 5 1
Incomplete remission or
refractory 2 7
Conditioning regimen NS
TBI-based 21 23
Non-TBI-based 3 2
GVHD prophylaxis
Tacrolimus + Methotrexate 25
Tacrolimus + Methotrexate + ATG 24
CMV indicates cytomegalovirus; TBI, total body irradiation; ATG,
antithymocyte globulin; NS, not significant.
We subdivided patients into two subgroups according to the use (group
3, n 5 24) or nonuse of ATG (group 4, n 5 25).
Table 1. Characteristics of Donors and Recipients in This
Study
Variables Number, Total 5 103
Age, donor/recipient;
median years (range)
28 (20-53)/36 (16-65)
Sex, donor/recipient; male:female 77:26/63:40
Sex matching,
Donor/ Recipient
M/M 46
M/F 31
F/M 15
F/F 11
ABO matching
Match 37
Major mismatch 33
Minor mismatch 27
Major/minor mismatch 6
Diagnosis, FAB classification
M0 5
M1 22
M2 41
M4 11
M5 7
M6 3
M7 1
Secondary AML 9
Hypoplastic 4
Cytogenetic abnormalities
Intermediate risk 63
High risk 40
Registries
CHIB, Korea 26
KMDP, Korea 52
TCMDR, Taiwan 13
JMDP, Japan 6
NMDP, USA 6
HLA mismatches, n 5 49
1 allele 25
2 alleles 4
1 antigen 14
1 antigen+1 allele 6
Stem cell sources
Bone marrow 70
Peripheral blood 33
Pretransplant status
1st complete remission 87
2nd complete remission 7
Incomplete remission
or refractory
9
Conditioning regimen
TBI-based 88
Non-TBI-based 15
GVHD prophylaxis
Tacrolimus + methotrexate 79
Tacrolimus + methotrexate + ATG 24
M indicates male; F, female; FAB, French-America-British; AML, acute
myelogenous leukemia; CHIB, Catholic Hematopoietic Information
Bank; KMDP, Korea Marrow Donor Program; TCMDR, Taiwan Tzu
Chi Marrow Donation Registry; JMDP, Japan Marrow Donor Program;
NMDP, National MarrowDonor Program; ATG, antithymocyte globulin;
TBI, total body irradiation; GVHD, graft-versus-host disease.
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All patients were treated according to our standard
protocol, which consisted of 3  7 idarubicin (IDA)
plus N4-behenoyl-1-b-D-arabinofuranosyl cytosine
(BH-AC) induction chemotherapy. Briefly, IDA was
administered intravenously at a dose of 12 mg/m2 for
30 minutes per day for 3 consecutive days, and BH2ACwas administered daily at a dose of 300 mg/m2 over 4
hours for 7 consecutive days. Based on the results of
the bone marrow (BM) examination (ie, depending on
the ratio of the remaining leukemic cells) on day 17
of chemotherapy, augmentation treatment was added
when a patient demonstrated .5% leukemic blasts.
For patients demonstrating .5% to 10% leukemic
blasts in the marrow on day 17 following the initial
chemotherapy treatment, BH-AC was provided i.v. at
a dose of 400 mg/m2/day for 3 more days (n 5 48).
For patients demonstrating .10% leukemic blasts on
day 17, IDA was administered i.v. at a dose of 8 mg/
m2 for 2 more days (days 18 and 19), plus BH-AC at
a dose of 300 mg/m2 for 3 more days (days 18, 19,
and 110; n 5 48). No additional treatment was
Biol Blood Marrow Transplant 15:704-717, 2009 707Prevention of aGVHD Using Low-Dose ATGprovided for patients with leukemic blast levels below
5% on day 17 (n 5 7), as previously described
[15,17219]. Patients who did not achieve CR with
our standard induction chemotherapy regimen re-
ceived a second induction with a different regimen: mi-
toxantrone 10 mg/m2/day i.v. for 3 days, intermediate-
dose cytosine arabinoside 1.0 g/m2/day i.v. every 12
hours for 4 days, and etoposide 100 mg/m2/day i.v.
for 3 days. For all patients with AML enrolled in this
study, we used basically the same induction and consol-
idation strategy. Almost all patients who achieved CR
received at least 1 more course of consolidation chemo-
therapy with the standard regimen at the center, ac-
cording to the donor search results and the clinical
condition of the patient. The first consolidation che-
motherapy consisted of a combination of BH-AC
(300 mg/m2 intravenously for 5 days) and IDA (12
mg/m2 intravenously for 3 days; n 5 94). A combina-
tion of mitoxantrone (12 mg/m2 i.v. for 3 days) and eto-
poside (100 mg/m2 i.v. for 5 days; n 5 30) was used in
patients who needed a second consolidation block.Transplantation from Matched or Mismatched
Unrelated Donors
Of the 103 patients, 54 received cells from 8/8
(HLA-A, -B, -Cw, -DR) perfect-match donors, and
the other 49 received cells from HLA-mismatched do-
nors (Table 1). The conditioning regimens are summa-
rized in Table 1. Overall, 70 patients received unrelated
donor BM cells, regardless of whether they achieved
CR. Owing to a weight discrepancy of more than 10
kg between the donor and recipient or the donor’s re-
fusal to have BM retrieval performed under general an-
esthesia, 33 patients received granulocyte-colony
stimulating factor (G-CSF)-mobilized uPBSCs. Of
the uPBSC donors, all were from domestic registries,
except for 7 cases from Taiwan and Western countries.
Since January 2005, we have prospectively studied the
addition of ATG at a dose of 1.25 mg/kg body weight
per day administered on days23 and22 in patients re-
ceiving transplants from mismatched unrelated donors
(n5 24); to prevent the development of aGVHD, ATG
was added together with our standard regimen of meth-
otrexate (MTX; 10 mg/m2 i.v. bolus on day 11, and
MTX 5 mg/m2 i.v. bolus on days 13, 16, and 111)
and tacrolimus starting at day 21. This particular
low-dose ATG protocol was based on reports showing
the development of manageable GVHD with a total
dose range of 4.5215 mg/kg [9,11,12]. In the absence
of aGVHD, tacrolimus was tapered by 25% biweekly,
beginning on day 120 posttransplantation. In some pa-
tients (n5 3), MTX was not administered on day 111
because the status of the patient did not warrant it, owing
to severe mucositis with or without fever. G-CSF (5 mg/
kg per day) was administered subcutaneously to all pa-
tients from day17 after transplantation until neutrophilrecovery. Time to hematopoietic recovery was defined
as an absolute neutrophil count (ANC) $0.5  109
cells/L and a platelet count $20  109 cells/L, with
no platelet transfusion needed for 3 consecutive days.
Engraftment was assessed by analyzing a routine mar-
row aspirate at day121. Graft failure or aplasia was de-
fined as the absence of hematologic recovery at day128
after transplantation. Toxicity grading was assessed us-
ing the WHO criteria [20]. All patients received prophy-
lactic antibiotics, starting from day214 until an ANC of
1.5  109 cells/L was achieved. All patients received
antifungal prophylaxis with itraconazole from day 214
to 160 posttransplantation. Pneumocystis carinii pneu-
monia prophylaxis with cotrimoxazole (Bactrim; Roche,
Basel, Switzerland) was given throughout conditioning,
discontinued 48 hours before stem cell infusion, and
then given from days 121 to 190. All blood compo-
nents given to patients were irradiated and leukocyte-
filtered before transfusion.Study Design and Statistical Analysis
We performed 2 different comparison studies with
4 groups of AML patients. First, we compared AML
patients who had a HLA-matched donor (group 1, n
5 54) with those who had a HLA-mismatched donor
(group 2, n 5 49). For the second comparison, we
then divided group 2, comprising patients who re-
ceived BM (n5 9) or PBSCs (n5 15) from allele(s)/an-
tigen-mismatched donors, into 2 groups: those who
received ATG for GVHD prophylaxis (group 3; n 5
24) and those who did not receive ATG (group 4, re-
ferred to as historic controls; n 5 25). The character-
istics of the patients in groups 3 and 4 are shown in
Table 2. No significant difference was observed be-
tween the 2 groups, except for ATG use and stem
cell source.
EFS was calculated from the date of stem cell infu-
sion until the date of engraftment failure, disease re-
currence, second malignancy, or death from any
cause, or last follow-up for patients who experienced
no events. Time to relapse was calculated from the
date of transplantation until the date of relapse. The
probability of relapse was estimated using the cumula-
tive incidence method. Cumulative incidence of
relapse (CIR) was defined based on morphologic evi-
dence of leukemia in BM or extramedullary organs.
To evaluate the probability of relapse, we censored pa-
tients who died from direct procedural toxicity or any
other cause not related to leukemia. Similarly, cumula-
tive incidences of aGVHD and cGVHDs were defined
based on clinical and/or pathologic documentation.
OS was calculated from the time of diagnosis to death.
The Kaplan-Meier method was used to calculate EFS,
OS, and the probability of relapse; the statistical signif-
icance of differences under various clinical conditions
was assessed using the log-rank test. Patients still alive
708 Biol Blood Marrow Transplant 15:704-717, 2009H.-J. Kim et al.and in CR were censored at their last follow-up. Uni-
variate analysis was performed to test for associations
of clinical outcome with demographic profiles of re-
cipients and donors, FAB subtypes, ABO mismatch be-
tween donor and recipient, infused CD341 cell dose,
conditioning regimen, degree of HLA mismatch, dis-
ease status before transplantation, multiple clinical
variables, stem cell source (PBSCs versus BM), pres-
ence or absence of aGVHD or cGVHD, use of
ATG, and year of transplant (2001-2005 versus
2005-2007), using the Cochran2Mantel2Haenszel
test. Factors associated with each clinical parameter
at P\ .20 in the univariate analyses were then used
in a multivariate Cox’s proportional hazards regression
analysis with a forward stepwise approach. For all anal-
yses, P\ .05 was deemed to be statistically significant.
The last follow-up date was December 31, 2007.A
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Infused CD341 Cell Dose and Engraftment
The median numbers of infused CD341 cells
were 4.7  106 cells/kg (range: 0.2-34.4) for the
whole population of AML patients (n 5 103); 4.2 
106 cells/kg (range: 1.2234.4) for patients in group 2
(n 5 49), who received transplants from allele(s)/an-
tigen-mismatched donors; 3.9  106 cells/kg (range:
1.2-4.8) for patients (n 5 33) who received BM and
5.2  106 cells/kg (range: 1.2234.4) for patients (n
5 16) who received PBSCs from mismatched do-
nors. All of the transplanted patients in group 2
were successfully engrafted, except for 1 (who was
also in group 4); this patient experienced primary
graft failure (2%) after receiving BM from a HLA-
mismatched (1 allele at HLA-DR) Korean donor.
Fortunately, this patient recovered with an autolo-
gous PBSC infusion after 4 weeks of marrow aplasia.
Sustained neutrophil and platelet engraftment wereFigure 1. Comparison of the estimated 6-year OS and EFS after allo-
geneic hematopoietic stem cell transplantation from multinational unre-
lated donors, n 5 103.obtained at a median of 12 days (range: 10-21) and
14 days (range: 11229), respectively, in group 3
and at 13 days (range: 7227) and 20 days (range:
7-50), respectively, in group 4.Survival Rate and Relapse
Overall, 72 (70%) of the 103 patients were alive.
The median follow-up period for all patients who
were event-free survivors was 21 months (range:
3275). The overall 5-year estimated EFS and OS rates
for uHSCT were 57% and 63%, respectively (Fig-
ure 1). The EFS and OS rates differed significantly
between the HLA-matched (group 1) and HLA-mis-
matched (group 2) patients (Figure 2). The 5-year es-
timated EFS and OS rates for group 2 were 43.5% 6
8.4% and 54.9% 6 8.2%, respectively.
Interestingly, the OS was significantly different be-
tween group 3 (68.5%6 13.1%) and group 4 (37.5%6
9.9%), although the EFS did not differ significantly be-
tween groups 3 and 4 (57.6%6 11.7% versus 37.5%6
9.9%, respectively) (Figure 3). The Kaplan-Meier esti-
mates of CIR were 25% overall (n 5 102) and 35% in
patients who received transplants from allele(s)/anti-
gen-mismatched donors (n 5 49) (Figure 4A). How-
ever, there was no statistical difference in CIR
between groups 3 and 4 (Figure 4B). In particular, ofMonths
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Figure 2. Comparison of the (A) OS and (B) EFS rates after selecting
donors with HLA-matches (group 1, n5 54; continuous line) and -mis-
matches (group 2, n 5 49; dashed line) after allogeneic hematopoietic
stem cell transplantation from multinational unrelated donors.
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Figure 3. Comparison of the (A) OS and (B) EFS rates between group
3 (with ATG, n 5 24; continuous line) and group 4 (without ATG,
n 5 25; dashed line), according to the use of ATG or not for patients
who received uHSCT from HLA-mismatched donors. Figure 4. The overall estimated CIR rate after allogeneic hematopoi-
etic stem cell transplantation from multinational unrelated donors,
n5 48 (A), and there was no definite difference of CIR between groups
3 and 4 (B).
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ceived uHSCT, 3 survived for a maximum of 78
months, 2 died because of severe veno-occlusive disease,
and 4 relapsed within 8 months after transplantation.
For all of the patients in group 2, their pre-uHSCT sta-
tus (ie, CR or incomplete remission/refractory) showed
a marginally significant association with relapse proba-
bility and OS, based on multivariate analysis, but no
correlation with EFS. The development of aGVHD
or cGVHD, even together with the severity of GVHDs,
showed no correlation with survival, relapse, or NRM
after uHSCT for group 2, by univariate analyses (Table
3). The use of ATG was significantly associated with
better OS (P5 .047) and lower NRM (P5 .014). Con-
ditioning with total body irradiation (TBI)/cyclophos-
phamide (Cy) also showed better OS (P 5 .027) and
lower NRM (P5 .038) (Table 4). We found no definite
factor correlated with relapse, except for age; multivar-
iate analysis revealed a lower rate of relapse in patients
.41 years of age (P 5 .029).GVHD
Of the 102 evaluated patients who received suc-
cessful primary engraftment, 44 (43%) developed
aGVHD, with grade I (17, 17%), grade II (16,
16%), grade III (9, 9%), or grade IV (2, 2%) reac-tions. cGVHD developed in 45/80 (56%) evaluated
patients and was of an extensive type in 19 (24%).
For patients in groups 1 and 2, the rates of aGVHD
were 48% and 38%, respectively, and the rates of
cGVHD were 56% and 56%, respectively.
Of 48 evaluated patients in group 2, 18 (38%) de-
veloped aGVHD, with grade I (9, 19%), grade II (6,
13%), grade III (3, 6%), or grade IV (0, 0%) reactions;
cGVHD, which developed in 18 of 32 (56%) evaluated
patients, was of an extensive type in 5 (16%). In groups
3 and 4, the rates of aGVHD were 33% and 43%, re-
spectively (P 5 .377), and the rates of cGVHD were
56% and 57%, respectively (P5 n.s.). Moderate to se-
vere aGVHD (grades II–IV) was identified in 10 (21%)
of 48 evaluable patients in group 2, and the rate dif-
fered significantly between groups 3 (2/24; 8%) and
4 (7/24; 29%) (P 5 .0389). The cumulative incidence
of developing aGVHD also showed a trend of signifi-
cant difference between groups 3 (33%; 95% confi-
dence interval [CI], 20%-46%) and 4 (60%; 95% CI,
49%-70%) (Figure 5A), although the cumulative inci-
dence of developing cGVHD was similar between
groups 3 (61%; 95% CI, 48%274%) and 4 (64%;
95% CI, 51%-77%) (Figure 5B). Three cases in group
Table 3. Influence of Multiple Variables on Various Clinical Outcomes by Univariate Analysis in All Transplants, expressed by P
Value
OS EFS Relapse NRM
Variables n % P n % P n % P n % P
Patient age, years .082 .045 .008 .734
#41 24 48.8 24 37.5 24 41.7 24 20.8
vs. >41 24 70.8 24 66.7 24 8.3 24 25.0
Donor age, years .562 .391 .509 .089
#28 24 62.5 24 58.3 24 29.2 24 12.5
vs. >28 24 54.1 24 45.3 24 20.8 24 33.3
Sex .715 .655 .276 .553
Match 26 61.5 26 57.7 26 30.7 26 19.2
vs. Mismatch 22 54.5 22 45.5 22 18.1 22 27.3
FAB classification .243 47.1 .609 .863 29.4 .432
M2 17 47.1 17 17 23.5 17
vs. Others 31 64.5 31 54.8 31 25.8 31 19.4
ABO .917 .977 .652 .975
Match 16 56.3 16 50.0 16 31.3 16 18.8
vs. Mismatch 32 59.4 32 53.1 32 21.9 32 25.0
Infused cell dose .007 .009 .213 .073
(CD34+, 106/kg)
#4.2 33 45.5 33 39.4 33 30.3 33 30.3
vs. >4.2 15 86.7 15 80.0 15 13.3 15 6.7
Pre-uHSCT status .013 .049 .139 .414
CR 39 66.7 39 58.9 39 20.5 39 20.5
vs. IR/refractory 9 22.2 9 22.2 9 44.4 9 33.3
Acute GVHD .465 .971 .405 .416
Yes 21 52.3 21 52.4 21 19.1 21 28.6
vs. No 27 62.9 27 51.9 27 29.6 27 18.5
Acute GVHD grade .852 .818 .290 .414
0-I 39 58.9 39 51.3 39 28.2 39 20.5
vs. II-IV 9 55.6 9 55.6 9 11.1 9 33.3
Chronic GVHD .691 .289 .321 .783
Yes 19 78.9 19 78.9 19 15.8 19 5.3
vs. No 13 84.6 13 61.5 13 30.8 13 7.7
Chronic GVHD .947 .947 .769 .551
Limited 14 78.6 14 78.6 14 14.3 14 7.1
vs. Extensive 5 80.0 5 80.0 5 20.0 5 0.0
Use of ATG .047 .257 .620 .003
Yes 24 75.0 24 62.5 24 29.2 24 4.4
vs. No 24 41.7 24 41.7 24 20.8 24 40.0
Conditioning .025 .047 .740 .006
TBI/Cy 26 73.1 26 65.4 26 26.9 26 7.7
vs. Others 22 40.0 22 36.4 22 22.7 22 40.9
Degree of
HLA-mismatch
.766 .991 .663 .644
1 allele 24 58.3 24 50.0 24 29.2 24 20.8
vs. >1 allele 4 50.0 4 50.0 4 25.0 4 25.0
Stem cell source .434 .463 .958 .291
BM 32 56.3 32 50.0 32 25.0 32 28.1
vs. PB 16 66.2 16 62.5 16 25.0 16 12.5
Recovery of ANC .434 .907 .858 .748
#13 33 54.6 33 51.5 33 24.2 33 24.2
vs. >13 days 15 66.7 15 53.3 15 26.7 15 20.0
Recovery of platelet .305 .686 .484 .229
#16 32 53.3 32 50.0 32 21.9 32 28.1
vs. >16 days 16 68.8 16 56.3 16 31.3 16 12.5
CMV Antigenemia/
DNAemia
.333 .325 .484 .683
posttransplant
- 27 74.1 27 66.7 27 18.5 27 25.9
vs.+ 21 61.9 21 57.1 21 28.6 21 19.0
Cytogenetics .521 .600 .866 .653
Intermediate 29 62.1 29 55.2 29 24.1 29 20.7
vs. Unfavorable 19 52.6 19 47.4 19 26.3 19 26.3
Year of transplant .099 .402 .740 .181
2001-2005 22 45.5 22 45.5 22 22.7 22 31.8
vs. 2006-2007 26 69.2 26 57.7 26 26.9 26 15.4
(Continued)
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aGVHDYes vs. No aGVHD severity 0-I vs. II-IV cGVHDYes vs. No cGVHD severity Lim vs. Ext
Variables n % P n % P n % P n % P
Patient age, years .773 .714 .098 .646
#41 24 41.7 24 16.7 14 42.9 6 33.3
vs. >41 24 45.8 24 20.8 18 72.2 13 23.1
Donor age, years .150 .010 .522 .256
#28 24 54.2 24 33.3 20 55.0 11 36.4
vs. >28 24 33.3 24 4.2 12 66.7 8 12.5
Sex .579 .268 .115 .358
Match 26 50.0 26 28.6 22 50.0 11 18.2
vs. Mismatch 22 40.6 22 14.7 10 80.0 8 37.5
FAB classification .335 .845 .699 .527
M2 17 35.3 17 17.7 22 66.7 13 16.7
vs. Others 31 50.0 31 20.0 10 59.1 6 30.8
ABO .105 .454 .934 .783
Match 16 37.5 16 25.0 11 63.6 7 38.6
vs. Mismatch 32 46.9 32 33.3 21 50.0 12 25.0
Infused cell dose .331 .152 .823 .913
(CD34+, 106/kg)
#4.2 33 48.5 33 24.2 18 61.1 11 27.3
vs. >4.2 15 33.3 15 6.7 14 57.1 8 25.0
Pre-uHSCT status .433 .218 .314 –
CR 39 41.0 39 15.4 27 55.6
vs. IR/refractory 9 55.6 9 33.3 5 80.0
Acute GVHD – – .288 .358
Yes 16 68.8 8 18.2
vs. No 16 50.0 11 37.5
Acute GVHD grade – – .469 –
0-I 25 56.0
vs. II-IV 7 71.4
Chronic GVHD – – – –
Yes
vs. No
Chronic GVHD – – – –
Limited
vs. Extensive
Use of ATG .090 .049 .623 .708
Yes 24 33.3 24 8.3 18 55.6 10 30.0
vs. No 24 54.2 24 29.2 14 64.3 9 22.2
Conditioning .828 .520 .192 .083
TBI/Cy 26 42.3 26 15.4 21 47.6 10 10.0
vs. Others 22 45.5 22 22.7 11 75.0 9 55.6
Degree of HLA-mismatch .010 .243 .941 .813
1 allele 24 25.0 24 8.3 17 58.8 10 30.0
vs. >1 allele 4 75.0 4 50.0 3 66.7 2 50.0
Stem cell source .005 .152 .692 .121
BM 32 57.6 32 24.2 21 61.9 13 15.4
vs. PB 16 13.3 16 6.7 11 54.5 6 50.0
Recovery of ANC .371 .348 .022 –
#13 33 39.4 33 15.2 20 75.0
vs. >13 days 15 53.3 15 26.7 12 33.3
Recovery of platelet .541 .437 .098 –
#16 32 40.6 32 21.9 20 72.2
vs. >16 days 16 5.0 16 12.5 12 42.9
CMV Antigenemia/
DNAemia
.093 .878 .028 .717
posttransplant
- 27 22.2 27 14.8 17 35.3 8 16.7
vs.+ 21 57.1 21 19.0 15 80.0 6 25.0
Cytogenetics .010 .832 .416 .615
Intermediate 29 29.6 29 18.5 14 64.7 11 18.2
vs. Unfavorable 19 68.4 19 21.1 18 50.0 7 28.6
Year of transplant .051 .034 .623 .708
2001-2005 22 59.1 22 31.8 14 64.3 9 22.2
vs. 2006-2007 26 30.8 26 7.7 18 55.6 10 30.0
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; Lim, limited type; Ext, extensive type; OS, overall survival;
EFS, event-free survival; NRM, nonrelapse mortality; uHSCT, unrelated donor hematopoietic stem cell transplantation; CR, complete remission; IR, in-
complete remission; TBI, total body irradiation; Cy, cyclophosphamide; BM, bone marrow; PB, peripheral blood; ANC, absolute neutrophil count; CMV,
cytomegalovirus; TRCs, transplant-related complications.
One patient in group 2 (who was also in group 4) was excluded in this analysis because of primary graft failure.
Table 3. (Continued)
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Table 4. Multivariate Analyses of Independent Variables Affecting Various Transplantation Outcomes in All Transplants
OS EFS Relapse NRM
Variables HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Patient age, years
#41 1 1 1 –
vs. >41 .3 (.1-1.3) .098 .3 (.1-1.0) .056 .1 (.02-.8) .029 –
Donor age, years
#28 – – – 1
vs. >28 – – – 3.8 (.6-23.9) .150
Se:
Match – – – –
vs. Mismatch – – – –
FAB classification
M2 – – – –
vs. Others – – – –
ABO
Match – – – –
vs. Mismatch – – – –
Infused cell dose
(CD34+, 106/kg)
#4.2 1 1 – 1
vs. >4.2 .3 (.1-2.1) .217 .3 (.1-1.5) .139 – .2 (.02-1.4) .101
Pre-uHSCT status
CR 1 1 1 –
vs. IR/refractory 5.4 (.9-31.1) .061 3.7 (.6-21.4) .148 4.5 (.8-23.5) .077 –
Use of ATG
Yes 1 – – 1
vs. No 3.7 (1.0-13.4) .047 – – 9.1 (1.5-53.6) .014
Conditioning
TBI/Cy 1 1 – 1
vs. Others 4.3 (1.2-15.5) .027 3.7 (.9-14.9) .064 – 7.0 (1.1-44.3) .038
Degree of HLA-mismatch
1 allele – – – –
vs. >1 allele – – – –
Stem cell source*
BM –* –* –* –*
vs. PB –* –* –* –*
Recovery of ANC
#13 – – – –
vs. >13 days – – – –
Recovery of platelet
#16 – – – –
vs. >16 days – – – –
CMV Antigenemia/DNAemia.
posttransplant
– – – – –
vs.+ – – – –
Cytogenetics
Intermediate – – – –
vs. Unfavorable – – – –
Year of transplant
2001-2005 1 – – –
vs. 2006-2007 .5 (.1-1.5) .195 – – –
aGVHDYes vs. No aGVHD severity 0-I vs. II-IV cGVHDYes vs. No CGVHD severity Lim vs. Ext
Variables HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Patient age, years
#41 – – 1 –
vs. >41 – – 7.3 (.9-54.5) .053 –
Donor age, years
#28 1 1 – –
vs. >28 .3 (.04-2.8) .313 .4 (.03-5.5) .060 – –
Sex
Match – – 1 –
vs. Mismatch – – 8.0 (.8-72.9) .063 –
FAB classification
M2 – – – –
vs. Others – – – –
(Continued )
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aGVHDYes vs. No aGVHD severity 0-I vs. II-IV cGVHDYes vs. No CGVHD severity Lim vs. Ext
Variables HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
ABO
Match 1 – – –
vs. Mismatch 1.6 (.5-4.9) .393 – – –
Infused cell dose
(CD34+, 106/kg)
#4.2 – – – –
vs. >4.2 – – – –
Pre-uHSCT status
CR – – – –
vs. IR/refractory – – – –
Use of ATG
Yes 1 1 – –
vs. No 23.6 (1.2-449.2) .035 5.4 (.9-29.4) .052 – –
Conditioning
TBI/Cy – – 1 1
vs. Others – – 5.8 (.7-46.1) .097 7.2 (.6-83.3) .114
Degree of HLA-mismatch
1 allele 1 – – –
vs. >1 allele 2.9 (1.3-6.6) .010 – – –
Stem cell source*
BM –* –* –* –*
vs. PB –* –* –* –*
Recovery of ANC
#13 – – 1 –
vs. >13 days – – .1 (.01-1.4) .084 –
Recovery of platelet
#16 – – 1 –
vs. >16 days – – .8 (.1-7.6) .804 –
CMV Antigenemia/DNAemia
posttransplant
– 1 – 1 –
vs.+ 8.8 (.5-155.5) .135 – .02 (.01-.6) .022 –
Cytogenetics
Intermediate 1 – – –
vs. Unfavorable 9.2 (1.2-73.3) .035 – – –
Year of transplant
2001-2005 1 1 – –
vs. 2006-2007 .3 (.1-1.0) .052 .2 (.03-.9) .046 – –
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; Lim, limited type; Ext, extensive type; OS, overall survival;
EFS, event-free survival; NRM, nonrelapse mortality; uHSCT, unrelated donor hematopoietic stem cell transplantation; TBI, total body irradiation; Cy,
cyclophosphamide; BM, bone marrow; PB, peripheral blood; ANC, absolute neutrophil count; CMV, cytomegalovirus; ATG, antithymocyte globulin; HR,
hazard ratio; CI, confidence interval.
*This parameter was excluded in multivariate analysis because most patients of (15/16) uHSCTwith peripheral blood stem cells received ATG. Those
patients who received ATG pretransplant resulted in a definitively low incidence of aGVHD compared to uHSCTwith bone marrow cells.
Table 4. (Continued)
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Among these 5 patients, 1 patient in group 3 developed
de novo-type cGVHD and finally relapsed at 5
months; the other patients have been successfully
managed.
The following potential risk factors for aGVHD
were identified in group 2 by univariate analysis: donor
age, ABO mismatch, use of ATG, cytomegalovirus
(CMV) antigenemia/DNAemia, degree of HLA mis-
match, stem cell source (BM versus PB), cytogenetics,
and year of transplant. Potential variables predicting
the severity of aGVHD were donor age, use of ATG,
stem cell source, and year of transplantation. Similarly,
patient age, sex mismatch between donor and recipient,
conditioning regimen, recovery phase of ANC (#13
versus.13 days), recovery phase of platelets (#16 ver-sus .16 days), and posttransplant CMV antigenemia/
DNAemia were potential risk factors for cGVHD,
with conditioning regimen and stem cell source being
potential risk factors for the severity of cGVHD (sec-
ond panel, Table 3).
In a multivariate analysis, nonuse of ATG, higher
degree of HLA mismatch (.1 allele), and unfavorable
cytogenetics were the most powerful predictive factors
for aGVHD (P\ .05). Interestingly, transplant after
2005 showed marginal significance for aGVHD (P 5
.052), but was the only statistically significant factor
for less severe aGVHD. CMV antigenemia/DNAemia
was the single most important risk factor for cGVHD.
No factor correlated with severity of cGVHD, except
for patient age.41 years, which showed marginal sig-
nificance (P 5 .053). The use of ATG was also
Figure 5. The overall estimated cumulative incidence of aGVHD and
cGVHDs after allogeneic hematopoietic stem cell transplantation from
multinational unrelated donors, n 5 48: (A) aGVHD, (B) cGVHD.
Figure 6. The overall estimated nonrelapse TRM rate after allogeneic
hematopoietic stem cell transplantation from multinational unrelated
donors, n 5 48 (A), but there was a statistically significant difference
between groups 3 and 4 (B).
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ond panel, Table 4).NRM and CMV Infection
The overall cumulative incidence of NRM in
group 2 was 29% (Figure 6A); unlike the CIR, the cu-
mulative incidence of NRM was significantly different
between groups 3 (16%; 95% CI, 4%-28%) and 4
(44%; 95% CI, 34%-54%) (P 5 .013; Figure 6B).
No patient died within the first 100 days following
uHSCT. Eight patients (16%) died more than 100
days after uHSCT, 7 from group 4 and 1 from group
3. Although we found no correlating survival factor as-
sociated with both aGVHD and cGVHDs in the entire
population of group 2 (Table 3), the causes of NRM,
especially in group 4, included the development of
mild to severe aGVHD, combined with pneumonia
and/or sepsis (n 5 5), thrombotic thrombocytopenic
purpura (n 5 2), and extensive-type progressive
cGVHD, specifically involving the lungs (n 5 1).
Among these patients, 2 cases of severe veno-occlusive
disease were combined with pneumonia.CMV reactivation (CMV antigenemia or DNAe-
mia) occurred in 32 (38%) of 102 patients. These in-
cluded 12 (50%) of 24 patients in group 3, who
received ATG, and only 9 (38%) of 24 patients in
group 4, who did not receive ATG (P 5 .23). How-
ever, 2 patients in group 4 died of intractable CMV
disease combined with pneumonia, and 1 died in asso-
ciation with moderate aGVHD. No deaths associated
with CMV infection occurred among the patients in
group 3.DISCUSSION
After uHSCT using multinational donors, Ko-
rean intermediate to high-risk patients with AML
had 63% and 57% 5-year estimated OS and EFS, re-
spectively, suggesting that uHSCT from worldwide
registries is a useful treatment option. Of note, our
data showed a 100% (25/25) engraftment rate using
Japanese, Taiwanese, and even Caucasian donors.
Our preliminary findings suggest that the use of mul-
tinational donor registries for unrelated donor HSCT
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our study, the average time to find an appropriate un-
related donor from all registries enrolled was about 4
months. If donors for patients with AML who are
categorized as high risk for relapse could be identified
in a timely fashion, they could receive uHSCT at an
optimal time, specifically when they are in CR. With-
out ATG in a conditioning regimen, however, severe
aGVHD and cGVHD in our previous data were by
far the most frequent causes of death after uHSCT.
These cases especially involved quality-of-life issues
in association with various lung complications and
applied specifically to patients with AML who re-
ceived uPBSCT from allele(s)/antigen-mismatched
donors.
Before 2005, our AML patients who received
PBSCs from either HLA-matched or -mismatched un-
related donors, without ATG for GVHD prophylaxis,
developed uncontrollable, moderate to severe aGVHD
and progressive, extensive-type cGVHD at unaccept-
able rates. This led us to design a strategy for using
ATG for the prevention of detrimental aGVHD in
these patients with AML. Since 2005, we have studied
the addition of ATG at a dose of 1.25 mg/kg body
weight per day on days 23 and 22 (total, 2.5 mg/kg)
for those receiving uPBSCs or transplants from
allele(s)/antigen-mismatched unrelated donors. Gen-
erally, these patients are categorized as high risk for
aGVHD and other transplant-related complications
because of the impact of HLA allele or antigen mis-
match immunobiology on clinical outcome. Specifi-
cally, ATG was added to prevent the development of
severe aGVHD after the use of uPBSCs from HLA-
mismatched unrelated donors. This particular low-
dose ATG protocol was originally based on other stud-
ies reporting the development of manageable aGVHD
at a total ATG dose range of 4.5215 mg/kg [9,11,12].
However, most of those reports revealed higher inci-
dences of CMV infection with ATG at these doses. In
a previous dose-finding experiment, we tried to reduce
the ATG dose to 2.5 mg/kg total, a very low dose that
has been used previously in clinical settings [15]. This
comparison among intermediate- to high-risk uHSCT
patients with AML demonstrated that the addition of
a relatively low dose of ATG in patients who received
either uPBSCs or BM from HLA-mismatched unre-
lated donors may be helpful in overcoming the antici-
pated poor outcome.
In the present study, we focused on the use ATG
in patients who received transplants from allele(s)/an-
tigen-mismatched unrelated donors. Importantly,
the strategy for GVHD prophylaxis differed accord-
ing to the period during which transplantation was
performed (before 2005 versus after 2005). Indeed,
we experienced a much lower incidence and less se-
verity of aGVHD after starting to use ATG in
2005. Consistent with these findings, the cumulativeincidence of aGVHD was encouragingly lower with
the use of ATG since 2005 than without ATG before
2005; the incidence of cGVHD appeared to be simi-
lar, as shown in Figure 5. The use of ATG was signif-
icantly associated with better OS and lower NRM.
However, the development of aGVHD or cGVHD,
even together with the severity of GVHD, showed
no correlation with survival, relapse, or NRM after
uHSCT, by univariate analyses; this finding may
change with more patients and longer follow-up. Al-
though the pre-uHSCT status of the patients (ie, CR
or IR/refractory) showed a marginally significant as-
sociation with relapse probability and OS, based on
multivariate analyses, our findings are consistent
with those of other studies in which disease status
just before transplantation was a major factor affect-
ing outcome. Our findings that conditioning with
TBI/Cy resulted in a better OS and lower NRM (al-
though EFS was only marginally significant) should
be examined in further detail.
Patients who received uHSCT from donors having
more than 1 allele mismatch showed a higher incidence
of aGVHD (hazard ratio, 2.9; 95% CI 1.3-6.6), but no
change in the severity of aGVHD. The degree of HLA-
mismatch in the present study was arbitrarily defined as
a mismatch of 1 allele versus more than 1 allele, but
a greater degree of HLA mismatch may have a greater im-
pact. To analyze permissible mismatches for uHSCT, we
need more time to enroll a more homogeneous population
of AML patients. The combined effect of the stem cell
source (PB versus BM) and the degree of HLA-mismatch
should also be studied. We included 24 AML patients in
group 3 who received BM or PBSCs from allele(s)/anti-
gen(s) mismatched, unrelated donors. Among these, the
15 patients who received uPBSCT with ATG showed
promising results for uHSCT, with a lower incidence
and less severity of aGVHD compared with those receiv-
ing BM. They also showed a much lower frequency of
NRM in association with severe infection. Thus, we antic-
ipate further studies on low-dose ATG for controlling var-
ious complications after uHSCT in the context of HLA-
mismatched BM versus HLA-mismatched PBSCs.
Of note, the patients with AML in group 3 who
received ATG pretransplantation showed a markedly
improved OS and relatively improved EFS, compared
with patients in group 4 (Figure 3), without any in-
crease in relapse rate, graft failure, or CMV infection,
based on stepwise statistical analyses. Although ATG
had no detectable positive effect on GVHD or EFS in
the entire population of group 2, when we divided the
population according to ATG use, we found a notably
lower incidence and less severity of aGVHD with
ATG use (group 3) than without ATG use (group
4). One noteworthy result is that the cumulative inci-
dence of aGVHD was much lower with low-dose
ATG than without ATG (Figure 5), and that the
difference was significant. Moreover, the relatively
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in considering the effects of ATG for preventing crit-
ical cases of aGVHD in association with better sur-
vival rates in the present study. Nevertheless, we
found that EFS and OS were the same for group 4
(no ATG), whereas EFS was relatively lower than
OS in group 3 (with ATG). We believe that this dif-
ference between the groups is attributable to a greater
number of early relapses in group 3 (7 versus 5 pa-
tients in group 4) and a relatively shorter posttrans-
plant follow-up duration in group 3 (2005-2007)
compared with group 4 (2001-2005); nevertheless,
there was no statistically significant difference in
CIR between the groups (Figure 4). Finally, multivar-
iate analysis revealed a lower rate of relapse in pa-
tients who were older than 41 years (P 5 .029).
However, this finding was likely derived from the
limitations of the present study. These include a rela-
tively small number of patients enrolled and a short-
term median follow-up period of around 2 years.
Furthermore, the majority of relapse cases, specifi-
cally in group 4, were younger than 41 years and
had IR/refractory status before uHSCT.
As we did not have a comparison study based on an
‘‘allogeneic donor versus no donor’’ strategy from the
beginning of diagnosing AML in 2001, we were unable
to perform an intent-to-treat analysis. A retrospective
review of our institution’s data on 435 patients who
had HLA-matched donors at CR, overall, showed
that we had performed allogeneic sibling (n 5 286)
and unrelated (n 5 103) HSCTs. Autologous (n 5
172) transplantations were also performed, as de-
scribed previously [19]. Other patients who achieved
CR but found no donor and had no plan for autologous
transplantation received 2 or 3 courses of consolida-
tion chemotherapy.
Our results in group 3 were similar to those of an
Italian study using 7.5 and 15 mg/kg ATG, in which
only 8%, compared with 21%, of patients who received
an HLA-mismatched uHSCT developed grades II–IV
aGVHD after using ATG [12]. Another promising
finding of the present study was the low rate of fatal in-
fections after using ATG, as first seen with the same low
dose of ATG (2.5 mg/kg total) in our previous study
[15]. We found only 2 cases of detrimental CMV infec-
tions, and these were in patients who did not receive
ATG. In addition, the overall NRM for those in group
3 who received conditioning with ATG was just 8%,
compared with 25% in group 2 (P5 .0133). No further
uncontrollable severe aGVHD and no complicating
lung cGVHD have occurred since the addition of
ATG in high-risk patients with AML who received
uHSCT from HLA-matched or -mismatched unre-
lated donors, even in those receiving PBSCs. Thus,
low-dose ATG may have an important role in immuno-
suppression, thereby reducing TRM when using
uPBSCs, particularly under HLA-mismatched condi-tions. Moreover, low-dose ATG may provide survival
benefits by reducing detrimental aGVHD and rejec-
tion, without serious infections, as similarly described
in other reports [9,12].
Although additional studies are needed with larger
study populations and longer follow-up, our results and
previous reports suggest that the addition of low-dose
ATG can feasibly prevent severe aGVHD after uHSCT
with allele(s)/antigen-mismatched donors as well as
with uPBSCs, with a considerably decreased rate of
NRM and without any negative effects on rates of re-
lapse or CMV infection, or other compromising results.ACKNOWLEDGMENTS
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